A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy

Abstract Aims Sudden cardiac death (SCD) is the most common cause of death in children with hypertrophic cardiomyopathy (HCM). The European Society of Cardiology (ESC) recommends consideration of an implantable cardioverter-defibrillator (ICD) if two or more clinical risk factors (RFs) are present, but this approach to risk stratification has not been formally validated. Methods and results Four hundred and eleven paediatric HCM patients were assessed for four clinical RFs in accordance with current ESC recommendations: severe left ventricular hypertrophy, unexplained syncope, non-sustained ventricular tachycardia, and family history of SCD. The primary endpoint was a composite outcome of SCD or an equivalent event (aborted cardiac arrest, appropriate ICD therapy, or sustained ventricular tachycardia), defined as a major arrhythmic cardiac event (MACE). Over a follow-up period of 2890 patient years (median 5.5 years), MACE occurred in 21 patients (7.5%) with 0 RFs, 19 (16.8%) with 1 RFs, and 3 (18.8%) with 2 or more RFs. Corresponding incidence rates were 1.13 [95% confidence interval (CI) 0.7–1.73], 2.07 (95% CI 1.25–3.23), and 2.52 (95% CI 0.53–7.35) per 100 patient years at risk. Patients with two or more RFs did not have a higher incidence of MACE (log-rank test P = 0.34), with a positive and negative predictive value of 19% and 90%, respectively. The C-statistic was 0.62 (95% CI 0.52–0.72) at 5 years. Conclusions The incidence of MACE is higher for patients with increasing numbers of clinical RFs. However, the current ESC guidelines have a low ability to discriminate between high- and low-risk individuals.

[1]  J. Kaski,et al.  Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom , 2018, European heart journal.

[2]  S. Colan,et al.  Long-Term Outcomes of Hypertrophic Cardiomyopathy Diagnosed During Childhood: Results From a National Population-Based Study , 2018, Circulation.

[3]  A. Keren,et al.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.

[4]  P. Elliott,et al.  Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis , 2017, European journal of preventive cardiology.

[5]  B. Maron,et al.  Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. , 2015, The American journal of cardiology.

[6]  F. Rutten,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[7]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[8]  C. Henrikson,et al.  Implanted Defibrillators in Young Hypertrophic Cardiomyopathy Patients: A Multicenter Study , 2013, Pediatric Cardiology.

[9]  P. Lambiase,et al.  A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy , 2013, Heart.

[10]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[11]  J. Towbin,et al.  Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. , 2009, Journal of the American College of Cardiology.

[12]  P. Elliott,et al.  Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy , 2008, Circulation. Cardiovascular genetics.

[13]  Wei Du,et al.  Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[14]  S. Colan,et al.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2007, Circulation.

[15]  P. Elliott,et al.  Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy , 2006, Heart.

[16]  J. Carlin,et al.  Clinical Features and Outcomes of Childhood Dilated Cardiomyopathy: Results From a National Population-Based Study , 2005, Circulation.

[17]  J. Carlin,et al.  Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study , 2005, Circulation.

[18]  Yvonne Vergouwe,et al.  Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. , 2005, Journal of clinical epidemiology.

[19]  John B Carlin,et al.  The epidemiology of childhood cardiomyopathy in Australia. , 2003, The New England journal of medicine.

[20]  E John Orav,et al.  The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.

[21]  O. Simell,et al.  Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. , 1997, American journal of epidemiology.

[22]  J. Deanfield,et al.  Hypertrophic cardiomyopathy: an important cause of sudden death. , 1984, Archives of disease in childhood.

[23]  G. Schwartz,et al.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.